Insmed Stock Jumps 28% on Experimental Hypertension Drug Trial Results

Insmed Stock Jumps 28% on Experimental Hypertension Drug Trial Results · Barrons.com

In This Article:

The company reports the results of a Phase 2b study for a drug meant to treat pulmonary arterial hypertension.